Biofysikalisk karakterisering av MYC-hämmare för läkemedelsutveckling
| Reference number | |
| Coordinator | MyCural Therapeutics AB |
| Funding from Vinnova | SEK 1 000 000 |
| Project duration | October 2024 - September 2025 |
| Status | Ongoing |
| Venture | Utlysning Infrastruktur for the development of accurate drug treatment |
| Call | Use infrastructures to develop precision medicine |
Purpose and goal
Altered expression of MYC is associated with multiple cancer types which makes MYC an attractive target for anti-cancer therapy. MyCural has developed selective and bioactive MYC-inhibitors. The goal is to establish a platform for characterizing these inhibitors, initially focusing on optimizing biophysical analysis methods and later adding structural analyses. The platform will be used to regularly identify and optimize MYC inhibitors, improving their effectiveness and drug properties.
Expected effects and result
The project is expected to deliver structural and binding data that will aid in optimizing MYC inhibitors into drug candidates. MyCural and ProLinc aim to gain more and improved tools for analyzing disordered proteins. In the long term, the goal is to conduct clinical trials with an optimized MYC inhibitor. With existing expertise and data provided by MyCural, the project has significant potential to achieve both its short-term and long-term objectives.
Planned approach and implementation
The project is structured into three work packages (WP) as follows: WP1: Development and optimization of methods for binding analysis and validation of MYC inhibitors to ensure efficiency. WP2: Characterization of protein-inhibitor complexes and structures, followed by the design of improved and more effective inhibitors. WP3: Chemical optimization of inhibitors and validation of their anti-MYC activity in various in vitro assays to assess function and potential.